Seres Therapeutics Inc (NAS:MCRB)
$ 0.78715 0.01125 (1.45%) Market Cap: 119.21 Mil Enterprise Value: 221.66 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 49/100

Seres Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 11:40PM GMT
Release Date Price: $5.74 (-0.86%)
Chris Shibutani
Goldman Sachs Group, Inc., Research Division - Research Analyst

Welcome, everybody. Thank you for joining us at the Goldman Sachs 44th Annual Healthcare Conference. And we're very pleased to wrap up our first day of the event here with folks from Seres; CEO, Eric Shaff; Terri Young, Chief Commercialization Officer. And I'm here together with my colleague, Stephen, who is going to help me do this discussion. We are really at so many interesting points with your company, but really probably speaking the microbiome space.

Questions & Answers

Chris Shibutani
Goldman Sachs Group, Inc., Research Division - Research Analyst

Eric, you and I go back many, many years in terms of thinking about how we're going to take this concept (inaudible) right? And get it to become sort of pharmaceuticalize? Is that a word? We'll see what the transcript shows up when I say that, right? Just understanding that this is like literally century of thoughtfulness, documentation science, et cetera, that we're navigating.

So pharmaceuticalize might not

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot